|
1
|
Jameson JL and Weetman AP: Disorders of
thyroid gland. Harrison's Principles of Internal Medicine. Kasper
DL, Braunwald E, Fauci AS, Hauser SL, Longo DL and Jameson JL:
(16th). McGraw-Hill. (New York, NY). 2104–2127. 2005.
|
|
2
|
Wille T, Müller B, Noth D, Bürgi U and
Diem P: Long-term follow up after antithyroid drug treatment in
Graves' disease. Praxis (Bern). 1994:1121–1127. 2006.(In German).
View Article : Google Scholar
|
|
3
|
Abraham P, Avenell A, Park CM, Watson WA
and Bevan JS: A systematic review of drug therapy for Graves'
hyperthyroidism. Eur J Endocrinol. 153:489–498. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weetman AP: Graves' disease. N Engl J Med.
343:1236–1248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bagnasco M, Venuti D, Caria M, Pizzamo G,
Ferrini O and Canonica GW: Methimazole, γ-”Interferon and Graves'
Disease. Thyroid Autoimmunity. Pinchera A, Ingbar SH, McKenzie JM
and Fenzi GF: (1st). Springer US. (New York, NY). 445–447. 1987.
View Article : Google Scholar
|
|
6
|
Bagnasco M, Venuti D, Ciprandi G, Pesce G,
Paolieri F and Canonica GW: The effect of methimazole on the immune
system is unlikely to operate directly on T lymphocytes. J
Endocrinol Invest. 13:493–499. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sato H, Minagawa M, Sasaki N, Sugihara S,
Kazukawa I, Minamitani K, Wataki K, Konda S, Inomata H, Sanayama K
and Kohno Y: Comparison of methimazole and propylthiouracil in the
management of children and adolescents with Graves' disease:
Efficacy and adverse reactions during initial treatment and
long-term outcome. J Pediatr Endocrinol Metab. 24:257–263. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Trepanier LA: Medical management of
hyperthyroidism. Clin Tech Small Anim Pract. 21:22–28. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Benker G, Vitti P, Kahaly G, Raue F,
Tegler L, Hirche H and Reinwein D: The European Multicenter Study
Group: Response to methimazole in Graves' disease. Clin Endocrinol
(Oxf). 43:257–263. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chinese Society of Endocrinology:
Guidelines for diagnosis and treatment of thyroid diseases in
China: Hyperthyroidism. Chi J Intern Med. 46:876–882. 2007.
|
|
11
|
World Health Organization. International
Council for Control of Iodine Deficiency Disorders and UNICEF:
Indicators for assessing Iodine Deficiency Disorders and their
control through salt iodization. (1st). World Health Organization.
(Geneva, Switzerland). 5–8, 13–35. 1994.
|
|
12
|
Werner SC: Modification of the
classification of the eye changes of Graves' disease. Am J
Ophthalmol. 83:725–727. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi BY: Antithyroid drugs: Rational and
normative application all the more. Zhong Hua Nei Fen Mi Dai Xie Za
Zhi. 25:245–246. 2009.(In Chinese).
|
|
14
|
Bai Y: Hyperthyroidism. Thyroid disease:
Basic and Clinic. 1st. Beijing Scientific and Technological
Literature Publishing House. (Beijing). 244–278. 2003.
|
|
15
|
Akamizu T, Moriyama K, Miura M, Saijo M,
Matsuda F and Nakao K: Characterization of recombinant monoclonal
antithyrotropin receptor antibodies (TSHRAbs) derived from
lymphocytes of patients with Graves' disease: Epitope and binding
study of two stimulatory TSHRAbs. Endocrinology. 140:1594–1601.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cooper DS: Antithyroid drugs. N Engl J
Med. 352:905–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lan L, Teng WP, Shi BY, Liu XJ, Li H, Liu
J, Wu XY, Xu L and Wang FX: Related factors in predicting relapse
of Graves' disease after treatment with antithyroid drug. Zhong Hua
Nei Fen Mi Dai Xie Za Zhi. 25:247–249. 2009.(In Chinese).
|
|
18
|
Vitti P, Rago T, Chiovato L, Pallini S,
Santini F, Fiore E, Rocchi R, Martino E and Pinchera A: Clinical
features of patients with Graves' disease undergoing remission
after antithyroid drug treatment. Thyroid. 7:369–375. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang PW, Liu RT, Tung SC, Chien WY, Lu YC,
Chen CH, Kuo MC, Hsieh JR and Wang ST: Outcome of Graves' disease
after antithyroid drug treatment in Taiwan. J Formos Med Assoc.
97:619–625. 1998.PubMed/NCBI
|
|
20
|
Laurberg P: Remission of Graves' disease
during anti-thyroid drug therapy. Time to reconsider the mechanism?
Eur J Endocrinol. 155:783–786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Manji N, Carr-Smith JD, Boelaert K,
Allahabadia A, Armitage M, Chatterjee VK, Lazarus JH, Pearce SH,
Vaidya B, Gough SC and Franklyn JA: Influences of age, gender,
smoking and family history on autoimmune thyroid disease phenotype.
J Clin Endocrinol Metab. 91:4873–4880. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshimura Noh J, Momotani N, Fukada S, Ito
K, Miyauchi A and Amino N: Ratio of serum free triiodothyronine to
free thyroxine in Graves' hyperthyroidism and thyrotoxicosis caused
by painless thyroiditis. Endocr J. 52:537–542. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holm IA, Manson JE, Michels KB, Alexander
EK, Willett WC and Utiger RD: Smoking and other lifestyle factors
and the risk of Graves' hyperthyroidism. Arch Intern Med.
165:1606–1611. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prummel MF and Wiersinga WM: Smoking and
risk of Graves' disease. JAMA. 269:479–482. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nordyke RA, Gilbert FI Jr and Harada AS:
Graves' disease. Influence of age on clinical findings. Arch Intern
Med. 148:626–631. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aizawa T, Ishihara M, Hashizume K, Takasu
N and Yamada T: Age-related changes of thyroid function and
immunologic abnormalities in patients with hyperthyroidism due to
Graves' disease. J Am Geriatr Soc. 37:944–948. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kelly GS: Peripheral metabolism of thyroid
hormones: A review. Altern Med Rev. 5:306–333. 2000.PubMed/NCBI
|
|
28
|
Morimoto K and Inouye K: A sensitive
enzyme immunoassay of human thyroid-stimulating hormone (TSH) using
bispecific F(ab')2 fragments recognizing polymerized alkaline
phosphatase and TSH. J Immunol Methods. 205:81–90. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Perrin A, Theretz A and Mandrand B:
Thyroid stimulating hormone assays based on the detection of gold
conjugates by scanning force microscopy. Anal Biochem. 256:200–206.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu N, Dai P, Gao A, Valiaho J, Kallio P,
Wang Y and Li T: Label-free and rapid electrical detection of hTSH
with CMOS-compatible silicon nanowire transistor arrays. ACS Appl
Mater Interfaces. 6:20378–20384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Quadbeck B, Janssen OE and Mann K:
Problems and new developments in the management of Graves' disease:
Medical therapy. Z Arztl Fortbild Qualitatssich. 98(Suppl 5):
37–44. 2004.(In German). PubMed/NCBI
|
|
32
|
Maugendre D, Gatel A, Campion L, Massart
C, Guilhem I, Lorcy Y, Lescouarch J, Herry JY and Allannic H:
Antithyroid drugs and Graves' disease - prospective randomized
assessment of long term treatment. Clin Endocrinol (Oxf).
50:127–132. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Quadbeck B, Roggenbuck U, Janssen OE, Hahn
S, Mann K and Hoermann R: Basedow Study Group: Impact of smoking on
the course of Graves' disease after withdrawal of antithyroid
drugs. Exp Clin Endocrinol Diabetes. 114:406–411. 2006. View Article : Google Scholar : PubMed/NCBI
|
